Diffuse Large B Cell Lymphoma of the Adult: Randomization Between High Dose Chemotherapy With Rituximab and CHOP 14-Rituximab
Frontline Therapy of Diffuse Large B Cell Lymphoma of the Adult ( 18 to 60 Years Old): Randomization Between High Dose Chemotherapy With Rituximab and CHOP 14 -Rituximab. Multicentric Randomized Prospective Trial.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Nantes, France
- Nantes university hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 et ≤ 60 and male and female
- Diffuse large B cell lymphoma according to WHO classification phénotype B CD 20 +
- Stage I et II tumor bulk > 7 cm and stage III et IV Ann Arbor.
- Non previously treated
- HIV négative
- Signed informed consent
Exclusion Criteria:
- Age < 18 and/or > 60 ans
- NHL not DLBCL
- Lymphoblastic Lymphoma
- Burkitt's Lymphoma
- Low grade Lymphoma transformed
- Primary CNS Lymphomal
- Post- transplantation Lymphoma
- CD20 negative
- Ann Arbor stage I or II without tumor bulk > 7 cm
- Previous treatment
- HIV positive
- Contre-indication to Rituximab use according to SmPC
- Contre-indication to high dose chemotherapy due to organ failure not related to the lymphoma
- Cancer or history of cancer with the exception of in situ cancer of the cervix or non-invasive skin epithelioma
- Patient not able to understand the proposed treatments
- Refusal to sign the informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: 2
|
High dose chemotherapy with rituximab including autologous stem cell support.
|
|
Active Comparator: 1
|
CHOP-14- Rituximab x 8 courses
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
3 years Event-free survival ( Kaplan Meier method)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
3 years overall survival
|
|
Prognostic impact of: Level of expression of protéine bcl2 protein in tumor cells; FCGR3A genotype; génomic profile (DNA microarray)on response, survival, and Event-Free-Survival
|
|
Cost
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Noel Milpied, MD, CHU Bordeaux
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Physiological Effects of Drugs
- Antirheumatic Agents
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Rituximab
Other Study ID Numbers
Other Study ID Numbers
- BRD 04/4-O
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.